论文部分内容阅读
目的 联合化学治疗Ⅳ期非小细胞肺癌 (NSCLC) 6 9例的疗效分析。方法 选择 6 9例NSCLCⅣ期初治患者 ,其中 35例接受顺铂 (DDP) 2 0mg/m2 第 1～ 5天 ;长春花碱酰胺 (VDS) 3mg/m2 第 1,8天 ;依托泊苷 (VP - 16 ) 10 0mg/m2 第 1～ 3天 ,2 1～ 2 8天为 1周期 ,至少 4个周期。 34例拒绝化疗者仅给予支持疗法。结果 中位生存期化疗组为 11.6月 ,对照组为 3.8月。 1年生存率化疗组为 4 5 .7% ,对照组为 0。治疗后Karnofsky评分化疗组明显优于对照组。化疗毒副作用主要表现为 ,胃肠道反应 94 .3% ,白细胞下降 91.4 % ,脱发 4 5 .7%。结论 联合化疗可延长Ⅳ期NSCLC生存期 ,改善生活质量。
Objective To evaluate the curative effect of combined chemotherapy on stage Ⅳ non-small cell lung cancer (NSCLC) in 69 cases. Methods Sixty-nine patients with initial stage IV NSCLC were enrolled in this study. Of the 35 patients who received cisplatin (DDP) 20 mg / m2 on days 1 to 5, vinca alkaloids (VDS) 3 mg / m2 on day 1 and 8, etoposide - 16) 100 mg / m2 on days 1 to 3, 21 to 28 days for 1 cycle, at least 4 cycles. 34 patients who refused to chemotherapy were given only supportive therapy. Results The median survival time was 11.6 months in the chemotherapy group and 3.8 months in the control group. The 1-year survival rate was 45.7% in the chemotherapy group and 0 in the control group. After treatment Karnofsky score chemotherapy group was significantly better than the control group. Side effects of chemotherapy mainly manifested as 94.3% of gastrointestinal reactions, white blood cells decreased 91.4%, hair loss 45.7%. Conclusion Combined chemotherapy can prolong the survival of stage Ⅳ NSCLC and improve the quality of life.